HC Wainwright Brokers Raise Earnings Estimates for BioCardia

BioCardia, Inc. (NASDAQ:BCDA) – Analysts at HC Wainwright boosted their FY2024 earnings estimates for BioCardia in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($3.52) per share for the year, up from their previous estimate of ($5.06). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2024 earnings at ($0.87) EPS, FY2025 earnings at ($1.22) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($1.03) EPS.

BioCardia Price Performance

Shares of BioCardia stock opened at $1.85 on Monday. The stock has a market cap of $3.92 million, a price-to-earnings ratio of -0.44 and a beta of 1.28. The firm’s 50-day moving average is $2.58 and its two-hundred day moving average is $3.30. BioCardia has a 1 year low of $1.84 and a 1 year high of $14.40.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.